Cibus Inc
NASDAQ:CBUS
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.16
3.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
C
|
Cibus Inc
NASDAQ:CBUS
|
92.5m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
393.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.7B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Cibus Inc
Glance View
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 228 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in developing and licensing plant traits to seed companies for royalties on seed sales. The firm is involved in gene-edited trait development, where plant traits (or specific genetic characteristics) that are indistinguishable from traits developed using traditional breeding are created using gene editing. Its patented RTDS technology platform includes the Trait Machine, which is a semi-automated stand-alone trait production facility. The Company’s Trait Machine materially changes the speed, breadth, and scale of trait development. The company is focused on the development of productivity traits and sustainable ingredients. The firm focuses on developing traits for addressing the sustainability challenges presented by climate change, disease, and pests.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Cibus Inc is -1 898.5%, which is above its 3-year median of -6 872%.
Over the last 3 years, Cibus Inc’s Operating Margin has decreased from -1 257.1% to -1 898.5%. During this period, it reached a low of -14 279.3% on Mar 31, 2024 and a high of -1 257.1% on Sep 30, 2022.